Related Experiment Video
Updated: Aug 22, 2025

A Suppressor Screen for the Characterization of Genetic Links Regulating Chronological Lifespan in Saccharomyces cerevisiae
Published on: September 17, 2020
Can sodium-glucose cotransporter 2 inhibitors 'spin the thread of life'?
Giuseppe Maltese1, Theocharis Koufakis2, Kalliopi Kotsa2
1School of Cardiovascular Medicine and Sciences, King's College London, London, UK; Department of Diabetes and Endocrinology, Epsom and St Helier University Hospitals, Surrey, UK.
Abstract:
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were first used as antidiabetic agents that lower the blood glucose levels by promoting glycosuria. In recent years, randomised clinical trials have demonstrated that SGLT2i reduce cardiovascular-renal events and all-cause mortality in people with and without diabetes. The cardio-renal benefits observed are independent of glucose lowering effect and multiple mechanisms have been proposed for these results. SGLT2i can exert anti-ageing effects on the vasculature and other body organs through several signalling pathways including the activation of the nuclear factor erythroid-2-related factor 2 and the induction of antioxidant enzymes. We speculate that the pro-longevity effects of the SGLT2i are mediated by soluble Klotho, an anti-ageing kidney-derived hormone and an emerging therapeutic target for cardio-renal diseases.
Insights
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) offer cardiovascular and renal benefits beyond glucose control. These SGLT2 inhibitors may promote longevity through anti-aging pathways, potentially involving soluble Klotho.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Endocrinology
Background:
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i) initially developed for diabetes management.
- Recent trials show SGLT2i reduce cardiovascular-renal events and mortality in diverse populations.
- Observed benefits extend beyond glucose lowering, suggesting novel mechanisms.
Purpose of the Study:
- To explore the anti-aging and pro-longevity effects of SGLT2 inhibitors.
- To investigate the role of soluble Klotho in mediating SGLT2i's cardio-renal benefits.
Main Methods:
- Review of randomized clinical trials and proposed mechanisms of action for SGLT2 inhibitors.
- Analysis of signaling pathways, including Nrf2 activation and antioxidant enzyme induction.
- Exploration of the association between SGLT2i and soluble Klotho levels.
Main Results:
- SGLT2i demonstrate significant cardio-renal protective effects.
- These benefits are independent of glycemic control.
- Potential anti-aging effects mediated by pathways like Nrf2 and antioxidant enzymes.
Conclusions:
- SGLT2 inhibitors possess pleiotropic effects contributing to cardiovascular and renal health.
- Soluble Klotho may be a key mediator of SGLT2i's pro-longevity and cardio-renal protective actions.
- SGLT2i represent a promising therapeutic target for age-related cardio-renal diseases.
More Related Videos
Related Concept Videos
Secondary Active Transport
Glucose Absorption Into the Small Intestine
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Membrane Proteins

